0

Close
 
Upcoming Allied Market Research
2023
Nasal Drug Delivery Technologies Market

Nasal Drug Delivery Technologies Market

by Dosage Form (Sprays, Drops Liquids, Powders, Gels, Others), by Container (Pressurized Containers, Non-pressurized Containers), by System (Multi-dose Systems, Bi-dose Systems, Unit-dose Systems), by Therapeutic Applications (Allergic Non-allergic Rhinitis, Nose Congestion, Vaccination, Others) and by End User (Home Care Settings, Hospitals): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Healthcare
Report Code: A02256
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Nasal Drug Delivery Technologies Market

Request Now !

Nasal delivery is used as a treatment of local infection in the nasal course & paranasal sinuses such as allergic & non-allergic sinusitis & rhinitis. The nasal drug delivery technique is used as to mitigate the problem of slow absorption of drugs, degradation before reaching the target site, and poor bioavailability. In addition, it helps in resolving issues related to the gastrointestinal tract and first-pass metabolism in liver. The significance of the nasal airway technology is to protect the lungs from hazardous contacts, rather than acting as a delivery route for drugs.

The global nasal drug delivery technology market is driven by rise in demand for alternative routes of drug delivery such as nasal sprays, increase in emphasis on pediatric & geriatric patients, growth in need of easy administration & better efficacy products, rise in demand for home healthcare devices, surge in adoption of self-administration practices, and advanced healthcare set-up. However, patents expiry of several drugs and side effects pertaining to drugs, such as nausea, irritation, and infections, restrain the market growth. Conversely, the development of OTC drugs by many pharmaceutical companies provides lucrative opportunities for market growth, especially for nasal drops and sprays sold as generic OTC drugs.

The global nasal drug delivery technology market is segmented on the basis of dosage form, container, system, therapeutic application, end user, and region. Based on dosage form, it is categorized into sprays, drops & liquids, powders, gels, and others. On the basis of container, it is bifurcated into pressurized containers and non-pressurized containers. Based on system, it is divided into multi-dose systems, bi-dose systems, and unit-dose systems. Based on therapeutic application, it is classified into allergic & non-allergic rhinitis, nose congestion, vaccination, and others. Based on end user, it is divided into home care settings and hospitals. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players operating in this market include Merck & Co., Inc., Novartis AG, Johnson & Johnson, Pfizer Inc., AstraZeneca, AptarGroup, Inc., GlaxoSmithKline plc., Aegis Therapeutics LLC., and Becton, Dickinson and Company.

Key Benefits

  • The report presents the market analysis of the global nasal drug delivery technology market along with the regional trends and future estimations.
  • It provides extensive information about the market segments to understand the market dynamics.
  • The key factors that drive, hamper, or provide opportunities to the market are provided in the report
  • Competitive landscape of the industry along with the profile analysis of market players is provided in the report.

 Nasal Drug Delivery Technologies Market Report Highlights

Aspects Details
By Dosage Form
  • Sprays
  • Drops & Liquids
  • Powders
  • Gels
  • Others
By Container
  • Pressurized Containers
  • Non-pressurized Containers
By System
  • Multi-dose Systems
  • Bi-dose Systems
  • Unit-dose Systems
By Therapeutic Applications
  • Allergic & Non-allergic Rhinitis
  • Nose Congestion
  • Vaccination
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
By End User
  • Home Care Settings
  • Hospitals
Key Market Players Merck & Co., Inc., Aegis Therapeutics LLC., AstraZeneca, Pfizer Inc., Novartis AG, GlaxoSmithKline plc., AptarGroup, Inc., Becton, Dickinson and Company., Johnson & Johnson
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY DOSAGE FORM

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Dosage Form

    • 4.2. Sprays

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Drops Liquids

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Powders

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Gels

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Others

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY CONTAINER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Container

    • 5.2. Pressurized Containers

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Non-pressurized Containers

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY SYSTEM

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By System

    • 6.2. Multi-dose Systems

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Bi-dose Systems

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Unit-dose Systems

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATIONS

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Therapeutic Applications

    • 7.2. Allergic Non-allergic Rhinitis

      • 7.2.1. Key Market Trends, Growth Factors and Opportunities

      • 7.2.2. Market Size and Forecast, By Region

      • 7.2.3. Market Share Analysis, By Country

    • 7.3. Nose Congestion

      • 7.3.1. Key Market Trends, Growth Factors and Opportunities

      • 7.3.2. Market Size and Forecast, By Region

      • 7.3.3. Market Share Analysis, By Country

    • 7.4. Vaccination

      • 7.4.1. Key Market Trends, Growth Factors and Opportunities

      • 7.4.2. Market Size and Forecast, By Region

      • 7.4.3. Market Share Analysis, By Country

    • 7.5. Others

      • 7.5.1. Key Market Trends, Growth Factors and Opportunities

      • 7.5.2. Market Size and Forecast, By Region

      • 7.5.3. Market Share Analysis, By Country

  • CHAPTER 8: NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY END USER

    • 8.1. Market Overview

      • 8.1.1 Market Size and Forecast, By End User

    • 8.2. Home Care Settings

      • 8.2.1. Key Market Trends, Growth Factors and Opportunities

      • 8.2.2. Market Size and Forecast, By Region

      • 8.2.3. Market Share Analysis, By Country

    • 8.3. Hospitals

      • 8.3.1. Key Market Trends, Growth Factors and Opportunities

      • 8.3.2. Market Size and Forecast, By Region

      • 8.3.3. Market Share Analysis, By Country

  • CHAPTER 9: NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY REGION

    • 9.1. Market Overview

      • 9.1.1 Market Size and Forecast, By Region

    • 9.2. North America

      • 9.2.1. Key Market Trends and Opportunities

      • 9.2.2. Market Size and Forecast, By Dosage Form

      • 9.2.3. Market Size and Forecast, By Container

      • 9.2.4. Market Size and Forecast, By System

      • 9.2.5. Market Size and Forecast, By Therapeutic Applications

      • 9.2.6. Market Size and Forecast, By End User

      • 9.2.7. Market Size and Forecast, By Country

      • 9.2.8. U.S. Nasal Drug Delivery Technologies Market

        • 9.2.8.1. Market Size and Forecast, By Dosage Form
        • 9.2.8.2. Market Size and Forecast, By Container
        • 9.2.8.3. Market Size and Forecast, By System
        • 9.2.8.4. Market Size and Forecast, By Therapeutic Applications
        • 9.2.8.5. Market Size and Forecast, By End User

      • 9.2.9. Canada Nasal Drug Delivery Technologies Market

        • 9.2.9.1. Market Size and Forecast, By Dosage Form
        • 9.2.9.2. Market Size and Forecast, By Container
        • 9.2.9.3. Market Size and Forecast, By System
        • 9.2.9.4. Market Size and Forecast, By Therapeutic Applications
        • 9.2.9.5. Market Size and Forecast, By End User

      • 9.2.10. Mexico Nasal Drug Delivery Technologies Market

        • 9.2.10.1. Market Size and Forecast, By Dosage Form
        • 9.2.10.2. Market Size and Forecast, By Container
        • 9.2.10.3. Market Size and Forecast, By System
        • 9.2.10.4. Market Size and Forecast, By Therapeutic Applications
        • 9.2.10.5. Market Size and Forecast, By End User

    • 9.3. Europe

      • 9.3.1. Key Market Trends and Opportunities

      • 9.3.2. Market Size and Forecast, By Dosage Form

      • 9.3.3. Market Size and Forecast, By Container

      • 9.3.4. Market Size and Forecast, By System

      • 9.3.5. Market Size and Forecast, By Therapeutic Applications

      • 9.3.6. Market Size and Forecast, By End User

      • 9.3.7. Market Size and Forecast, By Country

      • 9.3.8. France Nasal Drug Delivery Technologies Market

        • 9.3.8.1. Market Size and Forecast, By Dosage Form
        • 9.3.8.2. Market Size and Forecast, By Container
        • 9.3.8.3. Market Size and Forecast, By System
        • 9.3.8.4. Market Size and Forecast, By Therapeutic Applications
        • 9.3.8.5. Market Size and Forecast, By End User

      • 9.3.9. Germany Nasal Drug Delivery Technologies Market

        • 9.3.9.1. Market Size and Forecast, By Dosage Form
        • 9.3.9.2. Market Size and Forecast, By Container
        • 9.3.9.3. Market Size and Forecast, By System
        • 9.3.9.4. Market Size and Forecast, By Therapeutic Applications
        • 9.3.9.5. Market Size and Forecast, By End User

      • 9.3.10. Italy Nasal Drug Delivery Technologies Market

        • 9.3.10.1. Market Size and Forecast, By Dosage Form
        • 9.3.10.2. Market Size and Forecast, By Container
        • 9.3.10.3. Market Size and Forecast, By System
        • 9.3.10.4. Market Size and Forecast, By Therapeutic Applications
        • 9.3.10.5. Market Size and Forecast, By End User

      • 9.3.11. Spain Nasal Drug Delivery Technologies Market

        • 9.3.11.1. Market Size and Forecast, By Dosage Form
        • 9.3.11.2. Market Size and Forecast, By Container
        • 9.3.11.3. Market Size and Forecast, By System
        • 9.3.11.4. Market Size and Forecast, By Therapeutic Applications
        • 9.3.11.5. Market Size and Forecast, By End User

      • 9.3.12. UK Nasal Drug Delivery Technologies Market

        • 9.3.12.1. Market Size and Forecast, By Dosage Form
        • 9.3.12.2. Market Size and Forecast, By Container
        • 9.3.12.3. Market Size and Forecast, By System
        • 9.3.12.4. Market Size and Forecast, By Therapeutic Applications
        • 9.3.12.5. Market Size and Forecast, By End User

      • 9.3.13. Russia Nasal Drug Delivery Technologies Market

        • 9.3.13.1. Market Size and Forecast, By Dosage Form
        • 9.3.13.2. Market Size and Forecast, By Container
        • 9.3.13.3. Market Size and Forecast, By System
        • 9.3.13.4. Market Size and Forecast, By Therapeutic Applications
        • 9.3.13.5. Market Size and Forecast, By End User

      • 9.3.14. Rest Of Europe Nasal Drug Delivery Technologies Market

        • 9.3.14.1. Market Size and Forecast, By Dosage Form
        • 9.3.14.2. Market Size and Forecast, By Container
        • 9.3.14.3. Market Size and Forecast, By System
        • 9.3.14.4. Market Size and Forecast, By Therapeutic Applications
        • 9.3.14.5. Market Size and Forecast, By End User

    • 9.4. Asia-Pacific

      • 9.4.1. Key Market Trends and Opportunities

      • 9.4.2. Market Size and Forecast, By Dosage Form

      • 9.4.3. Market Size and Forecast, By Container

      • 9.4.4. Market Size and Forecast, By System

      • 9.4.5. Market Size and Forecast, By Therapeutic Applications

      • 9.4.6. Market Size and Forecast, By End User

      • 9.4.7. Market Size and Forecast, By Country

      • 9.4.8. China Nasal Drug Delivery Technologies Market

        • 9.4.8.1. Market Size and Forecast, By Dosage Form
        • 9.4.8.2. Market Size and Forecast, By Container
        • 9.4.8.3. Market Size and Forecast, By System
        • 9.4.8.4. Market Size and Forecast, By Therapeutic Applications
        • 9.4.8.5. Market Size and Forecast, By End User

      • 9.4.9. Japan Nasal Drug Delivery Technologies Market

        • 9.4.9.1. Market Size and Forecast, By Dosage Form
        • 9.4.9.2. Market Size and Forecast, By Container
        • 9.4.9.3. Market Size and Forecast, By System
        • 9.4.9.4. Market Size and Forecast, By Therapeutic Applications
        • 9.4.9.5. Market Size and Forecast, By End User

      • 9.4.10. India Nasal Drug Delivery Technologies Market

        • 9.4.10.1. Market Size and Forecast, By Dosage Form
        • 9.4.10.2. Market Size and Forecast, By Container
        • 9.4.10.3. Market Size and Forecast, By System
        • 9.4.10.4. Market Size and Forecast, By Therapeutic Applications
        • 9.4.10.5. Market Size and Forecast, By End User

      • 9.4.11. South Korea Nasal Drug Delivery Technologies Market

        • 9.4.11.1. Market Size and Forecast, By Dosage Form
        • 9.4.11.2. Market Size and Forecast, By Container
        • 9.4.11.3. Market Size and Forecast, By System
        • 9.4.11.4. Market Size and Forecast, By Therapeutic Applications
        • 9.4.11.5. Market Size and Forecast, By End User

      • 9.4.12. Australia Nasal Drug Delivery Technologies Market

        • 9.4.12.1. Market Size and Forecast, By Dosage Form
        • 9.4.12.2. Market Size and Forecast, By Container
        • 9.4.12.3. Market Size and Forecast, By System
        • 9.4.12.4. Market Size and Forecast, By Therapeutic Applications
        • 9.4.12.5. Market Size and Forecast, By End User

      • 9.4.13. Thailand Nasal Drug Delivery Technologies Market

        • 9.4.13.1. Market Size and Forecast, By Dosage Form
        • 9.4.13.2. Market Size and Forecast, By Container
        • 9.4.13.3. Market Size and Forecast, By System
        • 9.4.13.4. Market Size and Forecast, By Therapeutic Applications
        • 9.4.13.5. Market Size and Forecast, By End User

      • 9.4.14. Malaysia Nasal Drug Delivery Technologies Market

        • 9.4.14.1. Market Size and Forecast, By Dosage Form
        • 9.4.14.2. Market Size and Forecast, By Container
        • 9.4.14.3. Market Size and Forecast, By System
        • 9.4.14.4. Market Size and Forecast, By Therapeutic Applications
        • 9.4.14.5. Market Size and Forecast, By End User

      • 9.4.15. Indonesia Nasal Drug Delivery Technologies Market

        • 9.4.15.1. Market Size and Forecast, By Dosage Form
        • 9.4.15.2. Market Size and Forecast, By Container
        • 9.4.15.3. Market Size and Forecast, By System
        • 9.4.15.4. Market Size and Forecast, By Therapeutic Applications
        • 9.4.15.5. Market Size and Forecast, By End User

      • 9.4.16. Rest of Asia Pacific Nasal Drug Delivery Technologies Market

        • 9.4.16.1. Market Size and Forecast, By Dosage Form
        • 9.4.16.2. Market Size and Forecast, By Container
        • 9.4.16.3. Market Size and Forecast, By System
        • 9.4.16.4. Market Size and Forecast, By Therapeutic Applications
        • 9.4.16.5. Market Size and Forecast, By End User

    • 9.5. LAMEA

      • 9.5.1. Key Market Trends and Opportunities

      • 9.5.2. Market Size and Forecast, By Dosage Form

      • 9.5.3. Market Size and Forecast, By Container

      • 9.5.4. Market Size and Forecast, By System

      • 9.5.5. Market Size and Forecast, By Therapeutic Applications

      • 9.5.6. Market Size and Forecast, By End User

      • 9.5.7. Market Size and Forecast, By Country

      • 9.5.8. Brazil Nasal Drug Delivery Technologies Market

        • 9.5.8.1. Market Size and Forecast, By Dosage Form
        • 9.5.8.2. Market Size and Forecast, By Container
        • 9.5.8.3. Market Size and Forecast, By System
        • 9.5.8.4. Market Size and Forecast, By Therapeutic Applications
        • 9.5.8.5. Market Size and Forecast, By End User

      • 9.5.9. South Africa Nasal Drug Delivery Technologies Market

        • 9.5.9.1. Market Size and Forecast, By Dosage Form
        • 9.5.9.2. Market Size and Forecast, By Container
        • 9.5.9.3. Market Size and Forecast, By System
        • 9.5.9.4. Market Size and Forecast, By Therapeutic Applications
        • 9.5.9.5. Market Size and Forecast, By End User

      • 9.5.10. Saudi Arabia Nasal Drug Delivery Technologies Market

        • 9.5.10.1. Market Size and Forecast, By Dosage Form
        • 9.5.10.2. Market Size and Forecast, By Container
        • 9.5.10.3. Market Size and Forecast, By System
        • 9.5.10.4. Market Size and Forecast, By Therapeutic Applications
        • 9.5.10.5. Market Size and Forecast, By End User

      • 9.5.11. UAE Nasal Drug Delivery Technologies Market

        • 9.5.11.1. Market Size and Forecast, By Dosage Form
        • 9.5.11.2. Market Size and Forecast, By Container
        • 9.5.11.3. Market Size and Forecast, By System
        • 9.5.11.4. Market Size and Forecast, By Therapeutic Applications
        • 9.5.11.5. Market Size and Forecast, By End User

      • 9.5.12. Argentina Nasal Drug Delivery Technologies Market

        • 9.5.12.1. Market Size and Forecast, By Dosage Form
        • 9.5.12.2. Market Size and Forecast, By Container
        • 9.5.12.3. Market Size and Forecast, By System
        • 9.5.12.4. Market Size and Forecast, By Therapeutic Applications
        • 9.5.12.5. Market Size and Forecast, By End User

      • 9.5.13. Rest of LAMEA Nasal Drug Delivery Technologies Market

        • 9.5.13.1. Market Size and Forecast, By Dosage Form
        • 9.5.13.2. Market Size and Forecast, By Container
        • 9.5.13.3. Market Size and Forecast, By System
        • 9.5.13.4. Market Size and Forecast, By Therapeutic Applications
        • 9.5.13.5. Market Size and Forecast, By End User

  • CHAPTER 10: COMPETITIVE LANDSCAPE

    • 10.1. Introduction

    • 10.2. Top Winning Strategies

    • 10.3. Product Mapping Of Top 10 Player

    • 10.4. Competitive Dashboard

    • 10.5. Competitive Heatmap

    • 10.6. Top Player Positioning,2022

  • CHAPTER 11: COMPANY PROFILES

    • 11.1. Merck And Co., Inc.

      • 11.1.1. Company Overview

      • 11.1.2. Key Executives

      • 11.1.3. Company Snapshot

      • 11.1.4. Operating Business Segments

      • 11.1.5. Product Portfolio

      • 11.1.6. Business Performance

      • 11.1.7. Key Strategic Moves and Developments

    • 11.2. Novartis AG

      • 11.2.1. Company Overview

      • 11.2.2. Key Executives

      • 11.2.3. Company Snapshot

      • 11.2.4. Operating Business Segments

      • 11.2.5. Product Portfolio

      • 11.2.6. Business Performance

      • 11.2.7. Key Strategic Moves and Developments

    • 11.3. Johnson And Johnson

      • 11.3.1. Company Overview

      • 11.3.2. Key Executives

      • 11.3.3. Company Snapshot

      • 11.3.4. Operating Business Segments

      • 11.3.5. Product Portfolio

      • 11.3.6. Business Performance

      • 11.3.7. Key Strategic Moves and Developments

    • 11.4. Pfizer Inc.

      • 11.4.1. Company Overview

      • 11.4.2. Key Executives

      • 11.4.3. Company Snapshot

      • 11.4.4. Operating Business Segments

      • 11.4.5. Product Portfolio

      • 11.4.6. Business Performance

      • 11.4.7. Key Strategic Moves and Developments

    • 11.5. AstraZeneca

      • 11.5.1. Company Overview

      • 11.5.2. Key Executives

      • 11.5.3. Company Snapshot

      • 11.5.4. Operating Business Segments

      • 11.5.5. Product Portfolio

      • 11.5.6. Business Performance

      • 11.5.7. Key Strategic Moves and Developments

    • 11.6. AptarGroup, Inc.

      • 11.6.1. Company Overview

      • 11.6.2. Key Executives

      • 11.6.3. Company Snapshot

      • 11.6.4. Operating Business Segments

      • 11.6.5. Product Portfolio

      • 11.6.6. Business Performance

      • 11.6.7. Key Strategic Moves and Developments

    • 11.7. GlaxoSmithKline Plc.

      • 11.7.1. Company Overview

      • 11.7.2. Key Executives

      • 11.7.3. Company Snapshot

      • 11.7.4. Operating Business Segments

      • 11.7.5. Product Portfolio

      • 11.7.6. Business Performance

      • 11.7.7. Key Strategic Moves and Developments

    • 11.8. Aegis Therapeutics LLC.

      • 11.8.1. Company Overview

      • 11.8.2. Key Executives

      • 11.8.3. Company Snapshot

      • 11.8.4. Operating Business Segments

      • 11.8.5. Product Portfolio

      • 11.8.6. Business Performance

      • 11.8.7. Key Strategic Moves and Developments

    • 11.9. Becton, Dickinson And Company.

      • 11.9.1. Company Overview

      • 11.9.2. Key Executives

      • 11.9.3. Company Snapshot

      • 11.9.4. Operating Business Segments

      • 11.9.5. Product Portfolio

      • 11.9.6. Business Performance

      • 11.9.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR SPRAYS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR DROPS LIQUIDS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR POWDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR GELS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR PRESSURIZED CONTAINERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR NON-PRESSURIZED CONTAINERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR MULTI-DOSE SYSTEMS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR BI-DOSE SYSTEMS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR UNIT-DOSE SYSTEMS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR ALLERGIC NON-ALLERGIC RHINITIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR NOSE CONGESTION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR VACCINATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 20. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR HOME CARE SETTINGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 22. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA NASAL DRUG DELIVERY TECHNOLOGIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 25. NORTH AMERICA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 26. NORTH AMERICA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 27. NORTH AMERICA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 28. NORTH AMERICA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 29. U.S. NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 30. U.S. NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 31. U.S. NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 32. U.S. NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 33. U.S. NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 34. CANADA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 35. CANADA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 36. CANADA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 37. CANADA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 38. CANADA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 39. MEXICO NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 40. MEXICO NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 41. MEXICO NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 42. MEXICO NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 43. MEXICO NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 44. EUROPE NASAL DRUG DELIVERY TECHNOLOGIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 45. EUROPE NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 46. EUROPE NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 47. EUROPE NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 48. EUROPE NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 49. EUROPE NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 50. FRANCE NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 51. FRANCE NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 52. FRANCE NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 53. FRANCE NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 54. FRANCE NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. GERMANY NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 56. GERMANY NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 57. GERMANY NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 58. GERMANY NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 59. GERMANY NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 60. ITALY NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 61. ITALY NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 62. ITALY NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 63. ITALY NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 64. ITALY NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. SPAIN NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 66. SPAIN NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 67. SPAIN NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 68. SPAIN NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 69. SPAIN NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 70. UK NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 71. UK NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 72. UK NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 73. UK NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 74. UK NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 75. RUSSIA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 76. RUSSIA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 77. RUSSIA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 78. RUSSIA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 79. RUSSIA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 80. REST OF EUROPE NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 81. REST OF EUROPE NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 82. REST OF EUROPE NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 83. REST OF EUROPE NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 84. REST OF EUROPE NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 85. ASIA-PACIFIC NASAL DRUG DELIVERY TECHNOLOGIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 86. ASIA-PACIFIC NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 87. ASIA-PACIFIC NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 88. ASIA-PACIFIC NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 89. ASIA-PACIFIC NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 90. ASIA-PACIFIC NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 91. CHINA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 92. CHINA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 93. CHINA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 94. CHINA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 95. CHINA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 96. JAPAN NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 97. JAPAN NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 98. JAPAN NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 99. JAPAN NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 100. JAPAN NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 101. INDIA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 102. INDIA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 103. INDIA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 104. INDIA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 105. INDIA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 106. SOUTH KOREA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 107. SOUTH KOREA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 108. SOUTH KOREA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 109. SOUTH KOREA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 110. SOUTH KOREA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 111. AUSTRALIA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 112. AUSTRALIA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 113. AUSTRALIA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 114. AUSTRALIA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 115. AUSTRALIA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 116. THAILAND NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 117. THAILAND NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 118. THAILAND NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 119. THAILAND NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 120. THAILAND NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 121. MALAYSIA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 122. MALAYSIA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 123. MALAYSIA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 124. MALAYSIA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 125. MALAYSIA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 126. INDONESIA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 127. INDONESIA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 128. INDONESIA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 129. INDONESIA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 130. INDONESIA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 131. REST OF ASIA PACIFIC NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 132. REST OF ASIA PACIFIC NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 133. REST OF ASIA PACIFIC NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 134. REST OF ASIA PACIFIC NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 135. REST OF ASIA PACIFIC NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 136. LAMEA NASAL DRUG DELIVERY TECHNOLOGIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 137. LAMEA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 138. LAMEA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 139. LAMEA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 140. LAMEA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 141. LAMEA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 142. BRAZIL NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 143. BRAZIL NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 144. BRAZIL NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 145. BRAZIL NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 146. BRAZIL NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 147. SOUTH AFRICA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 148. SOUTH AFRICA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 149. SOUTH AFRICA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 150. SOUTH AFRICA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 151. SOUTH AFRICA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 152. SAUDI ARABIA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 153. SAUDI ARABIA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 154. SAUDI ARABIA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 155. SAUDI ARABIA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 156. SAUDI ARABIA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 157. UAE NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 158. UAE NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 159. UAE NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 160. UAE NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 161. UAE NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 162. ARGENTINA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 163. ARGENTINA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 164. ARGENTINA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 165. ARGENTINA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 166. ARGENTINA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 167. REST OF LAMEA NASAL DRUG DELIVERY TECHNOLOGIES, BY DOSAGE FORM, 2022-2032 ($MILLION)
  • TABLE 168. REST OF LAMEA NASAL DRUG DELIVERY TECHNOLOGIES, BY CONTAINER, 2022-2032 ($MILLION)
  • TABLE 169. REST OF LAMEA NASAL DRUG DELIVERY TECHNOLOGIES, BY SYSTEM, 2022-2032 ($MILLION)
  • TABLE 170. REST OF LAMEA NASAL DRUG DELIVERY TECHNOLOGIES, BY THERAPEUTIC APPLICATIONS, 2022-2032 ($MILLION)
  • TABLE 171. REST OF LAMEA NASAL DRUG DELIVERY TECHNOLOGIES, BY END USER, 2022-2032 ($MILLION)
  • TABLE 172. MERCK AND CO., INC.: KEY EXECUTIVES
  • TABLE 173. MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 174. MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 175. MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 176. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 177. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 178. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 179. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 180. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 181. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 182. JOHNSON AND JOHNSON: KEY EXECUTIVES
  • TABLE 183. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
  • TABLE 184. JOHNSON AND JOHNSON: OPERATING SEGMENTS
  • TABLE 185. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
  • TABLE 186. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 187. PFIZER INC.: KEY EXECUTIVES
  • TABLE 188. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 189. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 190. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 191. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 192. ASTRAZENECA: KEY EXECUTIVES
  • TABLE 193. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 194. ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 195. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 196. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 197. APTARGROUP, INC.: KEY EXECUTIVES
  • TABLE 198. APTARGROUP, INC.: COMPANY SNAPSHOT
  • TABLE 199. APTARGROUP, INC.: OPERATING SEGMENTS
  • TABLE 200. APTARGROUP, INC.: PRODUCT PORTFOLIO
  • TABLE 201. APTARGROUP, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 202. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
  • TABLE 203. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
  • TABLE 204. GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
  • TABLE 205. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
  • TABLE 206. GLAXOSMITHKLINE PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 207. AEGIS THERAPEUTICS LLC.: KEY EXECUTIVES
  • TABLE 208. AEGIS THERAPEUTICS LLC.: COMPANY SNAPSHOT
  • TABLE 209. AEGIS THERAPEUTICS LLC.: OPERATING SEGMENTS
  • TABLE 210. AEGIS THERAPEUTICS LLC.: PRODUCT PORTFOLIO
  • TABLE 211. AEGIS THERAPEUTICS LLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 212. BECTON, DICKINSON AND COMPANY.: KEY EXECUTIVES
  • TABLE 213. BECTON, DICKINSON AND COMPANY.: COMPANY SNAPSHOT
  • TABLE 214. BECTON, DICKINSON AND COMPANY.: OPERATING SEGMENTS
  • TABLE 215. BECTON, DICKINSON AND COMPANY.: PRODUCT PORTFOLIO
  • TABLE 216. BECTON, DICKINSON AND COMPANY.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION
  • FIGURE 2. GLOBAL NASAL DRUG DELIVERY TECHNOLOGIES MARKET
  • FIGURE 3. SEGMENTATION NASAL DRUG DELIVERY TECHNOLOGIES MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN NASAL DRUG DELIVERY TECHNOLOGIES MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALNASAL DRUG DELIVERY TECHNOLOGIES MARKET
  • FIGURE 11. NASAL DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION, BY BY DOSAGE FORM
  • FIGURE 12. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR SPRAYS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR DROPS LIQUIDS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR POWDERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR GELS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. NASAL DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION, BY BY CONTAINER
  • FIGURE 18. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR PRESSURIZED CONTAINERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR NON-PRESSURIZED CONTAINERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. NASAL DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION, BY BY SYSTEM
  • FIGURE 21. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR MULTI-DOSE SYSTEMS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR BI-DOSE SYSTEMS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR UNIT-DOSE SYSTEMS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. NASAL DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION, BY BY THERAPEUTIC APPLICATIONS
  • FIGURE 25. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR ALLERGIC NON-ALLERGIC RHINITIS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR NOSE CONGESTION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR VACCINATION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 28. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 29. NASAL DRUG DELIVERY TECHNOLOGIES MARKET SEGMENTATION, BY BY END USER
  • FIGURE 30. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 31. NASAL DRUG DELIVERY TECHNOLOGIES MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 32. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 33. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 34. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 35. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 36. COMPETITIVE DASHBOARD
  • FIGURE 37. COMPETITIVE HEATMAP: NASAL DRUG DELIVERY TECHNOLOGIES MARKET
  • FIGURE 38. Top player positioning, 2022
  • FIGURE 39. MERCK AND CO., INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. JOHNSON AND JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 51. ASTRAZENECA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 53. ASTRAZENECA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 54. APTARGROUP, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. APTARGROUP, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 56. APTARGROUP, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 57. GLAXOSMITHKLINE PLC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 58. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 59. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 60. AEGIS THERAPEUTICS LLC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 61. AEGIS THERAPEUTICS LLC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 62. AEGIS THERAPEUTICS LLC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 63. BECTON, DICKINSON AND COMPANY.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 64. BECTON, DICKINSON AND COMPANY.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 65. BECTON, DICKINSON AND COMPANY.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Nasal Drug Delivery Technologies Market

Start reading.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers